Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label randomised multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-fluorouracil (5-FU) plus oxaliplatin as second or higher line chemotherapy regarding clinical benefit.

Trial Profile

An open label randomised multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-fluorouracil (5-FU) plus oxaliplatin as second or higher line chemotherapy regarding clinical benefit.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms PANUSCO

Most Recent Events

  • 25 Sep 2014 Biomarkers information updated
  • 07 Jan 2013 Planned End Date changed from 1 Nov 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov.
  • 28 Jul 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-004696-22).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top